Stifel Financial Corp Bio N Tech Se Transaction History

Stifel Financial Corp

$85.8 Billion
Q1 2024

A detailed history of Stifel Financial Corp transactions in Bio N Tech Se stock. As of the latest transaction made, Stifel Financial Corp holds 6,377 shares of BNTX stock, worth $509,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,377

Previous 6,654 4.16%

Holding current value

$509,267

Previous $702,000 16.24%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$88.96 - $112.35 $24,641 - $31,120	-277 Reduced 4.16%	6,377 $588,000
Q4 2023 Feb 12, 2024	BUY	$90.91 - $112.75 $604,915 - $750,238	6,654 New	6,654 $702,000
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $247,239 - $373,597	-2,006 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$126.25 - $231.85 $1.04 Million - $1.91 Million	-8,243 Reduced 80.43%	2,006 $342,000
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $94,455 - $158,058	436 Added 4.44%	10,249 $2.64 Million

Q3 2021 Nov 15, 2021	SELL	$205.93 - $447.23 $1.01 Million - $2.18 Million	-4,884 Reduced 33.23%	9,813 $2.68 Million
Q2 2021 Aug 13, 2021	SELL	$113.32 - $241.49 $100,514 - $214,201	-887 Reduced 5.69%	14,697 $3.29 Million
Q1 2021 May 14, 2021	BUY	$85.73 - $119.5 $1.07 Million - $1.5 Million	12,531 Added 410.45%	15,584 $1.7 Million
Q4 2020 Feb 12, 2021	SELL	$72.71 - $129.54 $88,342 - $157,391	-1,215 Reduced 28.47%	3,053 $249,000
Q3 2020 Nov 16, 2020	SELL	$57.81 - $104.17 $142,675 - $257,091	-2,468 Reduced 36.64%	4,268 $295,000
Q2 2020 Aug 14, 2020	BUY	$38.58 - $66.74 $259,874 - $449,560	6,736 New	6,736 $449,000

Others Institutions Holding BNTX

# of Institutions

327

Shares Held

40.4M

Call Options Held

1.31M

Put Options Held

1.37M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $19.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account

Stifel Financial Corp Bio N Tech Se Transaction History